Hot Investor Mandate: China-Based Healthcare Fund Seeks to Invest $5-10M in Promising Biotech and Medtech Companies in USA, China, and Europe

21 Feb

A China-based healthcare fund focuses on global growth opportunities. The firm is based in Shanghai with several offices in the USA. In addition, the firm launched a sister fund that is focused on Seed to Series A opportunities in healthcare. Typical early-stage investment through the firm is US $5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China, Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, digital health and healthcare services. In terms of disease areas, the firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage. In the Diagnostics space, the firm only looks for products in the commercial stage from China.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: